Refludan

Refludan®

Lepirudin Hematology A recombinant hirudin for treating heparin-induced thrombocytopenia. See Heparin-induced thrombocytopenia.
References in periodicals archive ?
Lepirudin (50 mg; Refludan, Celgene Europe Ltd, Wndsor, United Kingdom) and argatroban (250 mg/2.
Lepirudin, which is recombinant hirudin, a specific thrombin inhibitor, is marketed as Refludan.
Aventis had filed an application for approval of the following indication: "anticoagulation in adult patients with acute coronary syndromes (unstable angina/acute MI without ST elevation," followed by the statement: "In this setting, Refludan has been shown to decrease the rate of CV death, new MI, or refractory angina (combined triple end point).
233 billion, excluding sales related to non-core former Pharmion products, Innohep and Refludan, to be divested.
In addition to testing for Bivalirudin, the Company can also rapidly manage Melagatran, Refludan, PEG-Hirudin and Argatroban.
Refludan is a leading treatment of thrombosis associated with the severe form of heparin-induced thrombocytopenia (HIT Type II).
The acquisition of Refludan represents an important step in the growth of Pharmion as a commercial organization," said Patrick J.
The approval covers the use of the test for managing patients suffering from Heparin Induced Thrombocytopenia (HIT) who receive Refludan while undergoing cardiopulmonary bypass.
In making the HDE submission, our goal was to provide physicians with a theranostic tool to better manage Refludan and this `high risk' group of patients.
Refludan is being used for cardiopulmonary bypass patients who are unable to receive unfractionated heparin because of the danger of serious adverse events.
PharmaNetics intends to submit study data to the Food and Drug Administration (FDA) for clearance to market the test for use with all patients being treated with Refludan.
The aPTT is subject to considerable site-to-site variability, thereby resulting in inaccurate anticoagulation status of some patients when used to assess the effect of a direct thrombin inhibitor, such as Refludan.